---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000074"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:20:12.402578+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M

## Summary
- Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.
- First GAAP profitable quarter: net income $1.3M vs loss $251M in Q1 2024; adjusted net income $136M.
- Adjusted diluted EPS $1.22 vs ($1.40) prior year; operating cash flow significantly improved.
- Shareholder approved renaming to BeOne Medicines and redomicile to Switzerland; investor R&D Day June 26.

## SEC filing metadata
- accession: 0001651308-25-000074
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/0001651308-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/bgne-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000074
- JSON: https://secwatch.observer/filing/0001651308-25-000074.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.